Premium
Vancomycin‐resistant enterococcus in pediatric oncology patients: An analysis of potential consequences of colonization and infection
Author(s) -
Kosack Amanda,
Riedel Elyn,
Kiehn Timothy E.,
Small Trudy N.,
Wexler Leonard H.,
Dunkel Ira J.
Publication year - 2009
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.21793
Subject(s) - medicine , incidence (geometry) , confidence interval , enterococcus , cumulative incidence , vancomycin resistant enterococcus , retrospective cohort study , blood cancer , colonization , chemotherapy , pediatric oncology , oncology , vancomycin , cancer , antibiotics , staphylococcus aureus , microbiology and biotechnology , physics , transplantation , genetics , bacteria , optics , biology
A retrospective analysis of 57 pediatric oncology patients with a baseline positive vancomycin‐resistant enterococcus (VRE) culture who subsequently received chemotherapy and/or radiation therapy was performed. The incidence of subsequent VRE infection was calculated using a competing risk analysis accounting for death from non‐VRE causes as a competing risk. Ten patients had subsequent VRE infection. The cumulative incidence of subsequent infection was 14% (7–27%, 95% confidence interval) at 1 year and 16% (9–29%, 95% confidence interval) at 2 years. None of the hypothesized risk factors appeared to differ between patients who developed a subsequent infection and those who did not. Pediatr Blood Cancer 2009;52:300–302. © 2008 Wiley‐Liss, Inc.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom